FDA examines cause of valsartan impurity
Executive Summary
The US Food and Drug Administration (FDA) says a “major operation” is underway to investigate and address the “troubling finding” of a toxic impurity in some generic versions of valsartan that could cause cancer, leading the agency to also test all drugs in valsartan’s therapeutic class for traces of the toxic material.
You may also be interested in...
Drug Safety Announcement Blitz Highlights Gottlieb's PR Savvy As Shutdown Drags On
Release of several different safety announcements showcases US FDA Commissioner Gottlieb's efforts to quell potential public concerns with an active communication strategy.
FDA’s Califf Calls For Return To Large, Simple Trials Without The ‘Useless Stuff’ That Slows Development
US FDA Commissioner Califf praises both Project Pragmatica and the ‘very powerful’ partnership between OCE Director Rick Pazdur and National Cancer Institute Director Monica Bertagnolli.
California Prop 65 Complaints Against OTC Generics? Ranitidine Could Be First And Last Target
Marketers of copies of national brand OTCs are required under FDA regulations to use the same labeling as the brand, a rule that in effect has limited complaints in California state court alleging Prop 65 violations with nonprescription drug labeling to targeting branded product marketers.